| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -3,851,442 | -2,910,094 |
| Net proceeds from sale of equity | 13,137,498 | - |
| Proceeds from employee stock purchases and option exercises | 409,296 | 1,116 |
| Net cash provided by financing activities | 13,546,794 | 1,116 |
| Effect of exchange rate changes on cash | 8,820 | 13,853 |
| Net increase in cash and cash equivalents | 9,704,172 | -2,895,125 |
| Cash and cash equivalents at beginning of period | 4,577,040 | - |
| Cash and cash equivalents at end of period | 14,281,212 | - |
MiNK Therapeutics, Inc. (INKT)
MiNK Therapeutics, Inc. (INKT)